

PIIL:SEC:NSE/BSE:77/2024-25

February 06, 2025

BSE Limited
Corporate Relationship Deptt.

PJ Towers, 25th Floor,

Dalal Street, Mumbai - 400 001

National Stock Exchange of India Ltd.
Exchange Plaza, Plot No. C/1, G-Block

Bandra Kurla Complex,

Bandra (East), Mumbai – 400 051

Code No. PIIND

Dear Sir/ Madam,

Code No.523642

Sub: Statement of deviation(s) or variation(s) in the use of proceeds of Qualified Institutional Placement ('QIP') for the quarter ended December 31, 2024

Pursuant to the provision of Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, it is submitted that there is no deviation or variation in utilization of proceeds of QIP from objects stated in the Placement Document dated July 08, 2020.

In terms of the SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019, the statement of **NIL** deviation(s) or variations(s) in utilization of proceeds of QIP for the quarter ended December 31, 2024, in prescribed format duly reviewed by the Audit Committee, is enclosed herewith

You are requested to kindly take same on record.

Thanking you,

Yours faithfully For **PI Industries Limited**

Sonal Tiwari Company Secretary ACS: 16638

A00. 10000

Encl: As above.

Statement of Deviation / Variation in utilisation of funds raised

Name of listed entity			PI Industries Limited Public Issues / Rights Issues/PreferentialIssues/ QIP / Others			
Mode of Fund Raising						
Date of Raising Funds			July 9, 2020 ₹ 19,749.66 Mn ("Net Proceeds") / ₹ 20,000 Mn (Issue size)			
Amount Raised			December 31, 2024			
Report filed for Quarter ended						
Monitoring Agency			Notapplicable			
Monitoring Agency Name, if applicable			Notapplicable			
Isthere a Deviation / Variation in use of funds raised If yes, whether the same is pursuant to change in terms of			NIL			
a contract or objects, which shareholders	h was approve		Notapplicab	- 10		
If Yes, Date of shareholder Approval			Notapplicable			
Explanation for the Deviation / Variation			Notapplicable			
Comments of the Audit Committee after review			Nil deviation			
Comments of the auditors, if any			NIL			
Objectsforwhichfundshave been a deviation, in the following		vhere there has				
Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of deviation/ Variation for the quarter according to applicable object	Remarks if any
To utilize the Net Proceeds for:- (i) funding the organic or inorganic growth opportunities in the area of its operations and adjacencies, (ii) other long-term capital requirements, (iii) investments in Subsidiaries, joint venture(s) and affiliate(s) (either through debt or equity or any convertible securities), (iv) pre-payment and / or repayment of outstanding borrowings and/ or, (v) general corporate requirements or any other purposes, as may be permissible under the applicable law and approved by our Board or its duly constituted committee.	Not Applicable	₹ 19,749.66 million ("Net Proceeds")	Not Applicable	₹, 16105.07 million	NIL	Out of the total funds utilized, - ₹674.99 million were utilized in the quarter ended December 31, 2022, and - ₹190 million were utilized in the quarter ended March 31, 2023 - ₹7,564.99 million were utilized in the quarter ended June 30, 2023 - ₹100 million were utilized in the quarter ended September 30, 2023 - ₹390 million were utilized in the quarter ended December 31, 2023 - ₹920 million were utilized in the quarter ended March 31, 2024 - ₹4948.76 million were utilized in th quarter ended September 30, 2024 - ₹1,316.33 million were utilized in the quarter ended December 31, 2024

Deviation or variation could mean:

(a) Deviation in the objects or purposes for which the funds have been raised or

(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or

(c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc.

Name of Signatory: Sanjay Agarwal

Designation: Group Chief Financial Officer and Head-Strategy and Integrated Development Cell Date: 06-02-2025

Place: Mulsai